Login / Signup

Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation.

Lori RegenstreifMarina SadikErin BeaulieuClaire BodkinLori KieferDale GuenterPatsy W P LeeFiona G Kouyoumdjian
Published in: Health & justice (2022)
People with opioid use disorders are overrepresented in correctional facilities, and are at high risk of opioid overdose. Despite the fact that buprenorphine/naloxone is the first line treatment for people with opioid use disorder, there are often institutional, clinical, and logistical barriers to buprenorphine/naloxone initiation in correctional facilities. Guided by the knowledge-to-action framework, this knowledge translation project focused on synthesizing knowledge and developing a tool for buprenorphine/naloxone initiation that was tailored to correctional facilities, including jails. This information and tool can be used to support buprenorphine/naloxone access for people in correctional facilities, in parallel with other efforts to address barriers to treatment initiation in correctional facilities.
Keyphrases
  • healthcare
  • quality improvement
  • chronic pain
  • pain management